These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28483516)

  • 1. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
    Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
    Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular changes in endometriosis-associated ovarian clear cell carcinoma.
    Worley MJ; Liu S; Hua Y; Kwok JS; Samuel A; Hou L; Shoni M; Lu S; Sandberg EM; Keryan A; Wu D; Ng SK; Kuo WP; Parra-Herran CE; Tsui SK; Welch W; Crum C; Berkowitz RS; Ng SW
    Eur J Cancer; 2015 Sep; 51(13):1831-42. PubMed ID: 26059197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive oxygen species downregulate ARID1A expression via its promoter methylation during the pathogenesis of endometriosis.
    Xie H; Chen P; Huang HW; Liu LP; Zhao F
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4509-4515. PubMed ID: 29131266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
    Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
    Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
    Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
    Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
    Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
    Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
    Xiao W; Awadallah A; Xin W
    Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A, Prostaglandin E2, and Its Receptor as Possible Predictors of Malignant Transformation of the Endometrium in Endometriosis.
    Dyatlova AS; Lin'kova NS; Polyakova VO; Samoshkin NG; Kvetnoi IM
    Bull Exp Biol Med; 2019 Aug; 167(4):504-507. PubMed ID: 31494765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
    Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
    Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
    Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
    Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
    Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
    Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing the progression of an endometrioma: Benign or malignant?
    Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
    Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.